CD8A and rheumatoid arthritis: Furthermore, in treated patients, we have demonstrated a reduction of circulating CD4+CD28neg and CD8+CD28neg T cells, which was correlated with an improvement of RA disease activity, suggesting that the co-stimulation blockade can prevent the generation of CD28neg T-cell populations [9,10].